ORIGINAL RESEARCH PAPER

Volume - 13 | Issue - 04 | April - 2024 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr

INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH

ANTIMICROBIAL RESISTANCE: A GLOBAL HEALTH THREAT

Pathology

Mritunjay Kaushik MBBS, 3rd Year Student, Noida International Institute Of Medical Sciences (NIIMS) Noida International University, Greater Noida, U.P.

Dr. Manjari Kishore* Associate Professor, Dept. Of Pathology, Noida International Institute Of Medical Sciences (NIIMS), Noida International University, Greater Noida, U.P. *Corresponding Author

ABSTRACT

Antimicrobial resistance (AMR) develops primarily through the process of natural selection and genetic adaptation in microorganisms. When antimicrobial drugs are used to treat infections, they exert selective pressure on microbial populations. Some microorganisms may possess genetic mutations or acquire resistance genes that enable them to survive the effects of the antimicrobial drugs. These resistant microorganisms then have a survival advantage and can multiply, leading to the proliferation of resistant strains.Antimicrobial resistance has a long history, dating back to the introduction of the first antimicrobial drugs. One of the earliest reported cases of antimicrobial resistance occurred shortly after the discovery of penicillin in the 1940s. By the late 1940s and early 1950s, penicillin-resistant strains of Staphylococcus aureus were already being observed. Since then, antimicrobial resistance has become a widespread and increasingly urgent global health concern, affecting a wide range of microorganisms and antimicrobial drugs.The misuse and overuse of antimicrobial drugs in human medicine, animal agriculture, and other sectors have accelerated the development and spread of antimicrobial resistance. This has led to a situation where many previously effective antibiotics and other antimicrobial agents are becoming less effective, threatening our ability to treat infections and posing significant challenges to healthcare systems worldwide. Efforts to combat antimicrobial resistance involve a multifaceted approach, including the development of new antimicrobial agents, improved stewardship of existing drugs, and enhanced infection prevention and control measures.

KEYWORDS

INTRODUCTION:

Antimicrobial Resistance refers to the ability of microorganisms to resist the effects of antimicrobial drugs, which were originally effective in treating infections caused by them.1-4 Over time, through natural selection and genetic adaptation, these microorganisms develop resistance mechanisms that render the medications ineffective.

Antimicrobial resistance poses a significant challenge to global public health, threatening the effectiveness of existing antibiotics and compromising our ability to treat common infections, thus increasing morbidity and mortality worldwide. Factors contributing to antimicrobial resistance include inappropriate use of antimicrobial drugs in humans, animals, and agriculture, as well as poor infection prevention and control practices.5-11 The emergence and spread of resistant bacteria, fungi, viruses, and parasites have rendered many of our most potent antimicrobial agents ineffective, exacerbating the burden of infectious diseases and challenging healthcare systems globally.

AMR necessitates the development of alternative treatment strategies and comprehensive efforts to promote appropriate antimicrobial use and stewardship to preserve the effectiveness of existing antimicrobial drugs.9-12 In this review, we examine the multifaceted nature of antibiotic resistance and explore strategies to combat this growing threat. From the development of novel antimicrobial agents to the implementation of stewardship programs and innovative treatment approaches, we discuss the latest advancements and ongoing efforts to mitigate the impact of antibiotic resistance on healthcare systems worldwide. Additionally, we highlight the importance of interdisciplinary collaboration, public awareness, and global cooperation in addressing this urgent health crisis.

Mechanism Of Developing AMR :

The development of antimicrobial resistance (AMR) involves a complex interplay of genetic, evolutionary, and ecological factors. AMR can arise through various mechanisms, each of which enables microorganisms to evade the effects of antimicrobial agents, such as antibiotics, antifungals, antivirals, and antiparasitic drugs. The key mechanisms of AMR include:

1. **Genetic Mutation:** Microorganisms, including bacteria, fungi, viruses, and parasites, possess the ability to adapt and evolve rapidly in response to selective pressure from antimicrobial agents. Genetic mutations in microbial genes can lead to alterations in the structure or function of antimicrobial targets, rendering them less susceptible to the inhibitory or bactericidal effects of antibiotics. For example, mutations in bacterial genes encoding antibiotic targets, such as bacterial ribosomes or enzymes involved in cell wall synthesis, can confer resistance by reducing the binding affinity of antibiotics to their targets or by altering the enzymatic activity required for antibiotic action.
2. **Horizontal Gene Transfer:** Horizontal gene transfer is a process by which microorganisms acquire resistance genes from other microorganisms in their environment, often through mechanisms such as conjugation, transformation, or transduction. This transfer of genetic material allows resistant traits to spread rapidly within bacterial populations, facilitating the dissemination of resistance genes across different species and genera. Horizontal gene transfer plays a significant role in the evolution and dissemination of antimicrobial resistance, particularly in environments with high microbial diversity and selective pressure from antimicrobial agents.
3. **Selection Pressure from Antimicrobial Use**: The overuse and misuse of antimicrobial agents in human and animal healthcare, agriculture, and the environment exert selective pressure on microbial populations, favoring the survival and proliferation of resistant strains. Prolonged or inappropriate use of antibiotics can create a favorable environment for the emergence and spread of resistant bacteria by providing selective advantage to pre-existing resistant mutants or by inducing the acquisition of resistance through genetic mutation or horizontal gene transfer. Furthermore, suboptimal dosing, incomplete treatment regimens, and non-compliance with prescribed antimicrobial therapies can contribute to the development of resistance by promoting the survival of partially resistant microbial populations.
4. **Antibiotic Pressure in the Environment**: Antimicrobial agents and their metabolites can accumulate in the environment through various routes, such as agricultural runoff, wastewater discharge, and improper disposal of pharmaceuticals. Environmental exposure to subinhibitory concentrations of antibiotics can select for resistant bacteria and genes in environmental reservoirs, such as soil, water, and wildlife. Additionally, environmental factors, such as temperature, pH, and nutrient availability, can influence the survival and persistence of resistant bacteria in the environment, further exacerbating the spread of AMR.

Global Challenge Of AMR1-9:

Antimicrobial resistance (AMR) poses a significant and complex global health threat due to its ability to render antimicrobial drugs ineffective against infections caused by resistant microorganisms. This phenomenon limits treatment options, leading to prolonged illnesses, increased morbidity and mortality rates, and higher healthcare costs. AMR also places a strain on healthcare systems worldwide, requiring more intensive treatments, longer hospital stays, and additional resources to manage resistant infections. Furthermore, the global spread of resistant microorganisms through international travel, trade, and migration complicates efforts to control the spread of AMR and undermines the effectiveness of public health interventions. In agriculture, the use of antimicrobials contributes to the development of resistance and poses risks to food safety and security. Economically, AMR results in significant costs, including increased healthcare expenditures, lost productivity, and impacts on agriculture and food production. Addressing the threat of AMR requires coordinated action at the local, national, and international levels to preserve the effectiveness of antimicrobial drugs and safeguard public health.

AMR is making surgeries and other related procedure even riskier, as surgical procedures often involve the use of antimicrobial drugs to prevent or treat infections that may occur as a result of the surgery. However, if the microorganisms causing these infections are resistant to the antimicrobial drugs commonly used, it can complicate the management of post-operative infections.

Patients undergoing surgery in environments where AMR is prevalent face a higher risk of developing infections that are difficult to treat. Resistant infections can lead to complications such as delayed wound healing, surgical site infections, bloodstream infections, and other serious complications, which may prolong hospital stays, increase morbidity and mortality rates, and necessitate additional treatments.

Moreover, in cases where antimicrobial drugs are ineffective due to resistance, surgeons may need to resort to alternative, potentially more invasive treatments, which can carry additional risks for patients. In a nut shell, antimicrobial resistance exacerbates the risks associated with surgical procedures by limiting treatment options for post-operative infections and increasing the likelihood of complications, highlighting the importance of effective infection prevention and control measures to mitigate these risks.

Several drugs have encountered challenges in their effectiveness due to antimicrobial resistance (AMR). Some examples include:

1. **Methicillin:** Methicillin was once a widely used antibiotic for treating Staphylococcus aureus infections, including methicillin-resistant Staphylococcus aureus (MRSA) infections. However, MRSA strains have developed resistance to methicillin and related β-lactam antibiotics, limiting their utility in treating these infections.
2. **Vancomycin:** Vancomycin is a potent antibiotic used to treat serious infections, including those caused by MRSA. However, the emergence of vancomycin-resistant Enterococcus (VRE) strains has reduced the effectiveness of vancomycin in treating certain infections.
3. **Fluoroquinolones:** Fluoroquinolone antibiotics, such as ciprofloxacin and infections. However, widespread use and misuse of fluoroquinolones have led to the development of resistance in many bacterial species, including Escherichia coli and Pseudomonas aeruginosa.
4. **Third-generation cephalosporins:** Third-generation cephalosporin antibiotics, such as ceftriaxone and cefotaxime, are commonly used to treat a range of bacterial infections. However, the emergence of extended-spectrum β-lactamase (ESBL)- producing bacteria has limited the effectiveness of these antibiotics in treating infections caused by Gram-negative bacteria.
5. **Carbapenems:** Carbapenem antibiotics, such as imipenem and meropenem, are often considered last-resort treatments for multidrug-resistant bacterial infections. However, the rise of carbapenem-resistant Enterobacteriaceae (CRE) strains, often known as "superbugs," has severely restricted the use of carbapenems in clinical practice.

Future Strategies to Combat AMR7-12:

Despite significant progress in addressing AMR, continued vigilance and innovation are essential to confront this evolving global health threat effectively. Future strategies to combat AMR must focus on harnessing emerging technologies, fostering international collaboration, and promoting sustainable practices across human health, animal health, and the environment.

In this subsection, we explore promising avenues for future action in the fight against AMR11-17:

1. **Harnessing Emerging Technologies:**
   Advancements in technology, including genomics, artificial intelligence, and machine learning, hold immense promise for understanding the molecular mechanisms of AMR, identifying novel drug targets, and accelerating the development of new antimicrobial agents. Genomic surveillance of resistant pathogens can provide insights into the genetic determinants of resistance and facilitate the tracking of transmission dynamics in real time. Machine learning algorithms can analyse vast datasets to predict antimicrobial resistance patterns and optimize treatment strategies, thereby enhancing clinical decision-making and patient outcomes. By embracing innovative technologies, we can empower researchers, clinicians, and policymakers to stay ahead of the curve in the battle against AMR.
2. **Promoting International Collaboration and Knowledge Sharing:**
   AMR knows no borders, underscoring the importance of international collaboration and knowledge sharing in tackling this global health threat. Collaborative initiatives, such as the Global Antimicrobial Resistance Surveillance System (GLASS) and the Tripartite Collaboration between the World Health Organization (WHO), the Food and Agriculture Organization of the United Nations (FAO), and the World Organisation for Animal Health (OIE), facilitate data exchange, capacity-building, and harmonized approaches to AMR surveillance and response. By fostering partnerships between countries, regions, and stakeholders, we can leverage collective expertise and resources to develop innovative solutions and implement effective interventions to combat AMR on a global scale.
3. **Promoting Sustainable Practices and Policies:**
   Addressing the root causes of AMR requires a holistic approach that integrates human health, animal health, and environmental considerations. Sustainable practices and policies aimed at reducing antimicrobial use in agriculture, promoting responsible antibiotic prescribing in healthcare settings, and minimizing environmental contamination from pharmaceutical waste are crucial for mitigating the drivers of AMR. Implementation of antimicrobial stewardship programs in veterinary medicine, regulation of antimicrobial use in food production, and investment in wastewater treatment infrastructure are among the key interventions needed to promote sustainable antimicrobial use and preserve the effectiveness of existing drugs. By adopting a One Health approach that recognizes the interconnectedness of human, animal, and environmental health, we can address AMR comprehensively and sustainably for the benefit of current and future generations.
4. **Collaboration with traditional systems of medicine:**
   Collaboration with traditional medicine systems like Ayurveda holds promise in combatting antimicrobial resistance (AMR) by leveraging their knowledge of natural remedies and medicinal plants. Integrating traditional therapies with modern healthcare may offer complementary approaches to managing infections, potentially discovering novel antimicrobial compounds and reducing reliance on conventional antimicrobial drugs. Research into plant-derived compounds used in traditional medicine can explore their efficacy against resistant microorganisms. Moreover, such collaboration fosters cultural acceptance and interdisciplinary research, contributing to holistic solutions for addressing AMR while respecting traditional practices and ensuring evidence-based approaches.

CONCLUSION:

In conclusion, AMR presents a multifaceted challenge to global public health, jeopardizing the effectiveness of antimicrobial drugs and posing significant risks to healthcare systems worldwide. As outlined in this review, AMR arises from complex mechanisms driven by natural selection and genetic adaptation, exacerbated by factors such as inappropriate antimicrobial use and poor infection control practices. The global response to AMR requires a comprehensive approach, encompassing the development of alternative treatment strategies, enhanced antimicrobial stewardship, and improved infection prevention and control measures. Collaborative efforts across disciplines and sectors are essential to address this urgent health crisis, safeguard the effectiveness of antimicrobial drugs, and ensure continued access to effective treatments for infectious diseases. Moving forward, continued research, surveillance, and investment in AMR mitigation efforts are imperative to mitigate the

PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr

impact of AMR on global health and ensure sustainable antimicrobial use for future generations.

REFERENCES:

1. Uchil RR, Kohli GS, Katekhaye VM, Swami OC. Strategies to combat antimicrobial resistance. J Clin Diagn Res. 2014 Jul;8(7) :ME01-4.
2. Dadgostar P. Antimicrobial Resistance: Implications and Costs. Infect Drug Resist. 2019 Dec 20;12:3903-3910.
3. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019:a systematic analysis. The Lancet; 2022;399(10325): P629-655.
4. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309-18.
5. Malathi V, Revathi K, Devaraj SN. Antimicrobial resistance an interface between animal and human diseases. Indian J Vet Anim Sci Res. 2020;43(2):113–4.
6. Webster DP, Young BC, Morton R, Collyer D, Batchelor B, Turton JF, et al. Impact of a clonal outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K. pneumoniae and Escherichia coli: an 11 year experience in Oxfordshire, UK. J Antimicrob Chemother. 2011;66(9):2126–35.
7. Delgado-Valverde M, Sojo-Dorado J, Pascual A, Rodriguez-Bano J. Clinical management of infections caused by multidrug-resistant Enterobacteriaceae. Ther Adv Infect Dis. 2013;1(2): 49–69.
8. Monaco M, Giani T, Raffone M, Arena F, Garcia-Fernandez A, Pollini S, et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, Novemberto April 2014. Euro Surveill. 2013;19(42):20939.
9. Andre M, Vernby A, Berg J, Lundborg CS. A survey of public knowledge and awareness related to antibiotic use and resistance in Sweden. J Antimicrob Chemother. 2010;65(6):1292–6.
10. Chokshi A, Sifri Z, Cennimo D, Horng H. Global Contributors to Antibiotic Resistance. J Glob Infect Dis. 2019;11(1):36–42.
11. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109 (7):309.
12. Founou RC, Founou LL, Essack SY. Clinical and economic impact of antibiotic resistance in developing countries: a systematic review and meta-analysis. PLoS One. 2017;12 :e0189621.
13. Shrestha P, Cooper BS, Coast J, et al. Enumerating the economic cost of antimicrobial resistance per antibiotic consumed to inform the evaluation of interventions affecting their use. Antimicrob Resist Infect Control. 2018;7(1):98.
14. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther Adv Drug Saf. 2014;5(6):229–241.
15. Chatterjee S, Poonawala H, Jain Y. Drug-resistant tuberculosis: is India ready for the challenge? Commentary. BMJ Glob Heal. 2018;3:971.
16. Bin ZS, Hussain MA, Nye R, Mehta V, Mamun KT, Hossain N. A review on antibiotic resistance: alarm bells are ringing. Cureus. 2017;9(6):e1403.
17. Langford BJ, Morris AM. Is it time to stop counselling patients to "finish the course of antibiotics"? Can Pharm J (Ott). 2017;150(6):349–350.